Inventor · disambiguated record
Christopher A. Luckhurst
Also filed as: LUCKHURST CHRISTOPHER · LUCKHURST CHRISTOPHER A · LUCKHURST CHRISTOPHER ANDREW
17 granted patents·17 pending applications·61 citations·filing 2003–2022
91Inventor score
Files withCHDI FOUNDATION INC15ASTRAZENECA AB7MISSION THERAPEUTICS LTD6LUCKHURST CHRISTOPHER3BÜRLI ROLAND W1
Top patents by PatentIndex Score
34 records- 0189US7956070B2Piperidines as chemokine modulators (CCR)ASTRAZENECA AB·Filed 2005·Granted Jun 7, 2011·17 cites·2 claims
- 0289US7902181B2Compounds 010ASTRAZENECA AB·Filed 2008·Granted Mar 8, 2011·20 cites·13 claims
- 0382US9617259B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2014·Granted Apr 11, 2017·3 cites·39 claims
- 0478US9505736B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2013·Granted Nov 29, 2016·3 cites·21 claims
- 0576US9562021B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2014·Granted Feb 7, 2017·3 cites·16 claims
- 0674US10106535B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2017·Granted Oct 23, 2018·1 cites·18 claims
- 0773US10457675B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2018·Granted Oct 29, 2019·1 cites·20 claims
- 0872US7517989B2Piperidine derivatives useful as modulators of chemokine receptor activityASTRAZENECA AB·Filed 2003·Granted Apr 14, 2009·5 cites·6 claims
- 0971US9783488B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2014·Granted Oct 10, 2017·1 cites·43 claims
- 1070US10053434B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2016·Granted Aug 21, 2018·1 cites·36 claims
- 1170US10047073B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2016·Granted Aug 14, 2018·1 cites·30 claims
- 1268US10065948B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2015·Granted Sep 4, 2018·1 cites·51 claims
- 1367US7495013B2Chemical compoundsASTRAZENECA AB·Filed 2004·Granted Feb 24, 2009·4 cites·19 claims
- 1462US2025034122A1Substituted n-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1558US2009069325A1Piperidine Derivatives Useful as Modulators of Chemokine Receptor ActivityASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 1656US2009118513A1Chemical CompoundsASTRAZENECA AB·Filed 2009·Application pending·0 cites
- 1754US12428413B2Rho kinase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2020·Granted Sep 30, 2025·0 cites·19 claims
- 1854US2023219939A1N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunctionMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1954US2023312580A11-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosisMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2054US2023303547A1N-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2153US2023119013A1N-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2250US2022315572A1Substituted cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2349US10105363B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2017·Granted Oct 23, 2018·0 cites·14 claims
- 2449US2019185463A1Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2018·Application pending·0 cites
- 2549US2019202795A1Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2018·Application pending·0 cites
- 2647US9855267B2Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2016·Granted Jan 2, 2018·0 cites·22 claims
- 2745US2009023733A1Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing ThemCAGE PETER·Filed 2007·Application pending·0 cites
- 2845US2006281726A1Piperidine derivatives for the treatment of chemokine or h1 mediated disease stateLUCKHURST CHRISTOPHER·Filed 2004·Application pending·0 cites
- 2944US2009118288A1N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine ReceptorASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 3044US2016031863A1Histone deacetylase inhibitors and compositions and methods of use thereofCHDI FOUNDATION INC·Filed 2014·Application pending·0 cites
- 3144US2006040984A1Novel piperidine derivatives for use in the treatment of chemokine medicated disease statesLUCKHURST CHRISTOPHER·Filed 2003·Application pending·0 cites
- 3241US2011201581A1Novel Compounds 010FURBER MARK·Filed 2011·Application pending·0 cites
- 3340US2006264463A1Chemical compoundsLUCKHURST CHRISTOPHER·Filed 2004·Application pending·0 cites
- 3435US9765054B2Histone deacetylase inhibitors and compositions and methods of use thereofBÜRLI ROLAND W·Filed 2012·Granted Sep 19, 2017·0 cites·27 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →